Navigation Links
AMRI Announces 3-Year Extension of Insourcing Contract

ALBANY, N.Y., Jan. 12, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) is pleased to announce the extension of a key insourcing relationship with a major pharmaceutical company designed to accelerate their chemistry and drug discovery efforts. The original insourcing collaboration, which commenced in 2011, is being extended significantly beyond its original termination date of December 2018 to December 31, 2021.

"Insourcing relationships provide the benefit of accelerating drug discovery, drug product and manufacturing efforts by maximizing the real-time exchange of scientific information and enabling scientists to rapidly adapt to changing project needs," said Michael P. Trova, Senior Vice President, Chemistry, AMRI. "We find these relationships are mutually beneficial and will be an important key to the long-term development and success of AMRI's DDS business unit. We look forward to finding new ways to deepen and extend these unique arrangements."

"The insourcing model is a fusion of the best elements of external outsourcing and in-house R&D activities," said Christopher Conway, Senior Vice President of Discovery and Development Services, AMRI. "With expertise in managing high performing groups of scientists, AMRI developed this business model in order to embed its own scientists into the customer's facility, allowing the customer to cost-effectively leverage their underutilized laboratory space and resources."

About Albany Molecular Research Inc.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, hormones, cytotoxic compounds and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations.

Forward-Looking Statements 
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties.  These statements include, but are not limited to, statements regarding the term or extension of customer contracts, the benefits to be derived by the company from its insourcing or other customer relationships, and the potential impact on the long-term results of the company's business unit(s).  Readers should not place undue reliance on our forward-looking statements.  The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company the company may not be able to predict and may not be within the company's control.  Factors that could cause such differences include, but are not limited to, the ability of the company to hire and retain qualified scientists to provide insourcing services, the risk of a decrease in customers' demand for the company's services, including but not limited to early termination of customer contracts, as well as those risks discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 16, 2015, and the company's other SEC filings.

For more information about AMRI, please visit our website at or follow us on Twitter (@amriglobal).


Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Provides Corporate Updates And Announces Preliminary Revenue For Fourth Quarter 2015
2. Mauna Kea Technologies Announces the Appointment of Joseph DeVivo as a Non-Executive Director
3. KaloBios Pharmaceuticals, Inc. Announces Board Changes and New Appointments
4. Bio2 Technologies, Inc. Announces Receipt of FDA 510(k) Clearance for a Fusion Implant System for Extremities Surgery
5. NuMedii, Inc. Announces New Indications Discovery Collaboration With Astellas
6. Medicure Announces Preliminary Revenue For Fiscal 2015
7. Worlds Largest Materials Science Catalog Announces Launch Of New Website
8. Agena Bioscience Announces the Expansion of its Headquarters in San Diego, California, to Better Serve its Growing Customer Base
9. Nevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2015 Revenue
10. Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002
11. Exact Sciences Announces Preliminary Fourth Quarter and Full Year 2015 Results
Post Your Comments:
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology:
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... , ... October 12, 2017 , ... IsoComforter, Inc. ( ... announced today the introduction of an innovative new design of the shoulder pad. ... you get maximum comfort while controlling your pain while using cold therapy. By utilizing ...
Breaking Medicine News(10 mins):